U.S. Paper and Forestry Products Stock News

Quest Diagnostics is expanding its drug screening capabilities to meet tighter global testing regulations. The company is rolling out oral fluid and fingerprint-based workplace testing as part of a broader service-focused offering. This shift targets growth opportunities in the global drug screening market beyond routine diagnostics. Quest Diagnostics, NYSE:DGX, is leaning into drug screening as regulators worldwide push for more rigorous and flexible testing options. With a current share...

If you are wondering whether Simpson Manufacturing is priced fairly or if the shares are getting ahead of themselves, the current setup makes valuation the key question. The stock last closed at US$177.89, with returns of 6.8% over 7 days, 8.0% year to date, 19.4% over 1 year, 63.9% over 3 years, and 76.6% over 5 years that many investors will want to put into context. Recent coverage of the company has focused on its position in the capital goods space and how investors are reassessing...

If you are wondering whether Mirion Technologies at around US$19.76 is offering value or stretching expectations, the recent share performance gives you some useful clues before looking at the valuation numbers. The stock has returned 3.6% over the last 7 days and 5.7% over the last 30 days, while the year to date return of a 17.1% decline contrasts with a 41.8% return over the past year and a 134.4% return over 3 years. Over the past year, investors have watched Mirion closely as it has...

Mama's Creations, Inc. has reported past full-year results for the period ended January 31, 2026, with sales of US$171.71 million and net income of US$5.29 million, alongside the upcoming May 1, 2026 appointment of veteran food industry executive Fred Halvin to its Board of Directors. The combination of double-digit top- and bottom-line growth and the addition of a seasoned M&A leader strengthens the company’s operational and governance profile. We’ll now examine how this strong full-year...

Gold.com (NYSE:GOLD) has acquired Sunshine Minting, Inc., expanding directly into minting and refining. The company has created a new Minting & Refining Division and appointed Jamie Meadows as its CEO. This move marks a shift in Gold.com's operational footprint beyond its existing business lines. For investors watching Gold.com at a share price of $44.51, this acquisition comes after substantial long term share price moves, including a 28.0% return year to date and a 202.8% return over five...

Giftify (NASDAQ:GIFT) has reported another strong update from its CardCash platform, this time on the demand side, and it helps complete the picture of how the marketplace is evolving.

Wondering if Vontier at around US$37.59 is offering genuine value or just looks inexpensive on the surface? This article breaks down what the current price really implies. The stock has returned 6.4% over the last 7 days and 4.4% over the past month, while the 1 year return sits at 24.7% and the year to date move is around a 0.6% decline. Recent coverage has focused on Vontier's role as a technology player in the industrial and mobility space. This has kept investor attention on how its...

If you are wondering whether Nordson's current share price lines up with its underlying worth or if expectations have run ahead of fundamentals, this article breaks down the numbers so you can judge the value story for yourself. Nordson's share price last closed at US$279.01, with returns of 5.1% over the past week, 4.3% over the last 30 days, 15.8% year to date and 54.5% over the past year. These moves in the share price sit against a backdrop of ongoing interest in industrial and capital...

Kopin (KOPN) has wrapped up FY 2025 with fourth quarter revenue of about US$8.4 million and basic EPS of roughly US$0.04, supported by trailing 12 month EPS of about US$0.01 and net income of around US$2.5 million on revenue of roughly US$39.3 million. Over recent quarters the company has seen quarterly revenue range from about US$8.4 million to US$12.0 million, while basic EPS has moved from losses of roughly US$0.03 to a profit of about US$0.04. This trailing period includes a US$16.2...

FB Financial (FBK) has put up a clean set of Q1 2026 numbers, with revenue of US$169.3 million and basic EPS of US$1.11, setting the tone against a trailing twelve month backdrop of US$557.7 million in revenue and EPS of US$2.76. Over recent quarters, revenue has moved from US$128.4 million in Q1 2025 to US$169.3 million in Q1 2026, while quarterly EPS has shifted from US$0.84 to US$1.11, giving you a clearer run rate to judge how sustainable current profitability and margins might be. See...

Rent the Runway (RENT) just posted a sharp swing in its latest FY 2026 third quarter numbers, reporting revenue of US$87.6 million and basic EPS of US$13.69 on net income of US$76.5 million. Earlier quarters in the same fiscal year showed losses at both the EPS and net income line. Over recent periods, revenue has moved from US$75.9 million in Q3 2025 to US$76.4 million in Q4 2025, then to US$69.6 million in Q1 2026, US$80.9 million in Q2 2026 and now US$87.6 million. Basic EPS shifted from a...

New Fortress Energy (NFE) closed out FY 2025 with Q4 revenue of US$415.9 million and a basic EPS loss of US$2.77, alongside a net income loss of US$788.4 million. Over the last six reported quarters, revenue has ranged from US$301.7 million to US$668.2 million, while basic EPS has swung between a small profit of US$0.03 and a loss of US$2.77. This gives investors a wide view of how top line scale and per share losses have moved together. With trailing 12 month revenue at about US$1.5 billion...

If you are wondering whether Dyne Therapeutics at around US$19.81 is still offering value or has already priced in much of the story, the next sections aim to put the current share price in context. The stock has recently posted returns of 9.1% over 7 days, 10.5% over 30 days, 7.1% year to date and 152.4% over the past year, which can change how investors see both its potential and its risks. Recent news flow around Dyne Therapeutics has centered on its progress as a biotechnology name and...

If you are wondering whether Star Bulk Carriers is priced attractively or already reflects its potential, this article breaks down what the current share price could mean for you as an investor. At a last close of US$24.73, the stock has returns of 2.6% over 7 days, 13.2% over 30 days, 27.7% year to date and 78.8% over 1 year. These recent moves are front of mind when thinking about value and risk. Recent coverage has focused on Star Bulk Carriers within the broader shipping sector,...

Wondering whether Silgan Holdings at around US$41.87 is priced for opportunity or caution? This article breaks down what the current share price could be implying about value. The stock is up 6.1% over the last 7 days and 0.6% over the past month, yet year to date it is only up 1.5%, and the 1 year return sits at a 14.0% decline. That mix of recent gains and a weaker 1 year and 3 year record, with returns of a 14.0% decline and 16.2% decline respectively, has kept Silgan on the radar for...

Wondering if ImmunityBio at around US$7.30 is still priced for opportunity or already reflecting the story most investors see? This article is built to help you frame that question clearly. The stock has delivered a 261.4% return year to date and 162.6% over the past year. However, the last 30 days show a 13.0% decline and the last week a 6.4% gain, which can change how you think about both potential and risk. Recent coverage of ImmunityBio has focused on how its clinical pipeline and...

Amentum Holdings (NYSE:AMTM) played an essential role in NASA's Artemis II mission, the first crewed launch of the Artemis program. The company supported ground systems operations, critical launch support, safety systems deployment, and post mission recovery of the Orion spacecraft. This work contributes to NASA's goal of a sustained lunar presence and future deep space missions. Amentum operates as a mission critical engineering and operations partner to US government agencies and other...

Byrna Technologies Inc. has reported past first‑quarter 2026 results showing sales rising to US$29.05 million while net income fell to US$0.80 million, reducing earnings per share versus the prior year. The new CEO outlined a push toward brick‑and‑mortar and dealer growth amid weaker ecommerce conversion, as analysts adjusted their views on the company’s prospects. Now we’ll explore how weaker online conversion but growing retail channels may reshape Byrna’s existing investment narrative and...

Over the last 7 days, the United States market has risen by 4.2%, contributing to a 29% increase over the past year, with earnings forecasted to grow by 16% annually. In this environment of growth, identifying stocks that may be trading below their estimated value can offer investors potential opportunities for capitalizing on future gains.

Over the last 7 days, the United States market has risen by 4.2%, contributing to a significant 29% increase over the past year, with earnings forecasted to grow by 16% annually. In this thriving environment, growth companies with substantial insider ownership can be particularly appealing as they often signify strong confidence from those closely involved in their operations.

The United States market has shown impressive strength, climbing 4.2% over the last week and achieving a remarkable 29% increase over the past year, with earnings projected to grow by 16% annually. In this thriving environment, dividend stocks that offer consistent payouts and potential for growth can be appealing options for investors seeking to enhance their portfolios.

Peabody Energy (NYSE:BTU) reported that first quarter sales volumes at its Centurion mine in Australia are below prior expectations. The shortfall stems from greater than anticipated commissioning challenges at the new operation. Following this update, an analyst reduced the price target on Peabody Energy shares. Peabody Energy is a large coal producer with operations across the United States and Australia, and the Centurion mine is one of its key new Australian assets. Commissioning issues...

Artivion (AORT) is back in focus after the FDA approved the NEXUS Aortic Arch System, a minimally invasive device for aortic arch disease that also activates the company’s option to acquire developer Endospan. See our latest analysis for Artivion. The FDA approval appears to have revived interest in Artivion, with a 7 day share price return of 15.31% and a 1 day move of 2.50% lifting the stock to $38.57. However, the 1 year total shareholder return of 66.75% contrasts with weaker year to date...

It looks like Pentair plc ( NYSE:PNR ) is about to go ex-dividend in the next 2 days. The ex-dividend date is one...